Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Accumulated Expenses (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Accumulated Expenses data on record, last reported at $17.0 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 87.88% year-over-year to $17.0 million; the TTM value through Dec 2025 reached $17.0 million, down 87.88%, while the annual FY2025 figure was $17.0 million, 87.88% down from the prior year.
  • Accumulated Expenses reached $17.0 million in Q4 2025 per APLS's latest filing, up from $7.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $140.2 million in Q4 2024 and bottomed at $723000.0 in Q3 2022.
  • Average Accumulated Expenses over 5 years is $53.7 million, with a median of $30.4 million recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: crashed 99.22% in 2022, then surged 1766.1% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $103.2 million in 2021, then fell by 7.85% to $95.1 million in 2022, then soared by 34.34% to $127.8 million in 2023, then increased by 9.68% to $140.2 million in 2024, then plummeted by 87.88% to $17.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $17.0 million in Q4 2025, $7.1 million in Q3 2025, and $30.4 million in Q2 2025.